

BIOCON GROUP

FACT SHEET

March 2011

FY 2011 vs. FY 2010

Q4 FY 2011 vs. Q4 FY 2010

BIOCON LIMITED (CONSOLIDATED) AUDITED		
BALANCE SHEET		<i>(Rs. Crores)</i>
	March-11	March-10
<u>SOURCES OF FUNDS</u>		
Share Capital	100	100
Reserves & Surplus	1,939	1,658
Total Shareholder's Funds	2,039	1,758
Minority interest	38	34
Deferred Tax Liability	50	51
Secured Loans	204	332
Unsecured Loans	130	182
Total Loan Funds	334	514
TOTAL	2,460	2,356
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	1,357	1,241
Intangible Assets	240	173
Investments - Liquid Funds	400	383
Investments - Others	61	47
Inventories	414	372
Sundry debtors	520	446
Cash and bank balances	441	140
Loans and advances	128	134
Total Current Assets	1,503	1,092
Less: Current liabilities	1,100	580
Net Current assets	403	512
TOTAL	2,460	2,356

**BIOCON LIMITED (CONSOLIDATED) AUDITED
PROFIT & LOSS STATEMENT** (Rs. Crores)

Particulars	FY 11	FY 10	Variance
<u>INCOME</u>			
Biopharmaceuticals - Biocon	1,483	1,181	26%
- Axicorp	971	906	7%
Contract research	318	281	13%
Total Sales	2,771	2,368	17%
Other income	43	37	
Total Income / Revenues	2,814	2,405	17%
<u>EXPENDITURE</u>			
Material & Power Costs	1,615	1,414	14%
Staff costs	292	229	28%
Research & Development	118	79	51%
Other Expenses	159	176	-9%
Manufacturing, staff & other expenses	2,184	1,896	15%
PBDIT /EBITDA	630	509	24%
Interest and finance charges	26	17	52%
PBDT	604	492	23%
Depreciation	157	140	12%
PBT	447	352	27%
Taxes	72	49	48%
Profit before minority interest	375	303	24%
Add/(less): Minority interest	(8)	(10)	-22%
NET PROFIT (PAT)	368	293	25%
EPS Rs.	18.4	14.7	

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

Biopharmaceuticals - Biocon includes licensing income of Rs 155 crores in FY 2011 vs. Rs 51crores in FY 2010.

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT** (Rs Crores)

Particulars	Q4 FY 11	Q4 FY 10	Variance
<u>INCOME</u>			
Biopharmaceuticals - Biocon	380	335	13%
- Axicorp	233	247	-6%
Contract research	89	74	20%
Total Sales	702	657	7%
Other income	15	9	
Total Income / Revenues	717	666	8%
<u>EXPENDITURE</u>			
Material & Power Costs	425	406	5%
Staff costs	77	61	27%
Research & Development	22	20	13%
Other Expenses	35	40	-14%
Manufacturing, staff & other expenses	558	526	6%
PBDIT /EBITDA	158	139	14%
Interest and finance charges	6	3	71%
PBDT	153	136	12%
Depreciation	40	37	8%
PBT	113	99	14%
Taxes	11	14	-23%
Profit before minority interest	102	85	20%
Add/(less): Minority interest	(1)	(4)	
NET PROFIT (PAT)	101	81	25%
EPS Rs	5.0	4.0	

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

Biopharmaceuticals - Biocon includes licensing income of Rs 32crores in Q4 FY 2011 vs. Rs 20crores in Q4 FY 2010